Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02254746
Other study ID # CHUV-DO-HYPORT-2013
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date September 2014
Est. completion date March 2024

Study information

Verified date February 2024
Source Centre Hospitalier Universitaire Vaudois
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to test the safety and efficacy of Stereotactic Body Radiation Therapy (SBRT) in localized prostate carcinoma in patients for whom the standard treatment is the irradiation of the entire prostate gland with or without seminal vesicles accompanied or not by hormonal therapy. In light of the accumulating clinical evidence favoring the use of hypo fractionation, SBRT regimen might constitute a much more convenient non-invasive and highly efficient outpatient therapy.


Description:

Primary objective phase I: To irradiate the prostate gland which might albeit contain microscopic disease with tumoricidal doses of SBRT, and to escalate the dose of SBRT in the visible prostatic tumor towards the best tumoricidal dose without exceeding the normal tissue tolerance and toxicity in patients with organ confined T2-T3 N0 prostate carcinoma. Primary objective phase II: To determine the rate of acute toxicity grade 2 or more defined as toxicity occurring immediately after the first fraction of radiotherapy and up to 90 days after the start of radiotherapy treatment. Secondary objectives phase II: - To determine efficacy measured by PSA failure using Phoenix definition. - To determine long-term late toxicity (>90 days after treatment start). Exploratory endpoint phase II: • To determine the feasibility of achieving dose constraints in the organs at risk using high technology radiotherapy.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 27
Est. completion date March 2024
Est. primary completion date April 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - All patients must be willing and capable to provide informed consent - Histologic confirmation of prostate adenocarcinoma - T2-T3 tumors, N0 (clinically by no evidence of metastatic lymph nodes on CT or MRI) - No direct evidence of regional or distant metastases - PSA less than or equal to 50 µg/ml - Visible gross tumor at the prostate endorectal coil MRI. - The ultrasound or MRI based volume estimation of the patient's prostate gland no greater than 70g or 70cc - No significant urinary obstructive symptoms; IPSS score must be = 15 (alpha blockers allowed) - Patient must have undergone an endorectal coil magnetic resonance image (MRI) of the prostatic gland (before rectal spacer if any), - Patient must have undergone the following assessments in case of PSA = 20µg/L, and/or T3 tumor and/or Gleason Score = 8: - bone scan - Chest abdominal and pelvis computed tomography (CT) scan - If tumor is localized at less than 3 mm from the rectum a rectal spacer is mandatory. Patient accepts the rectal spacer to be injected before treatment starts - Patient accepts to have one planning MRI after the injection of rectal spacer (without endorectal coil) - Patient accepts the preparation of the bladder (bladder full), before the planning MRI, planning CT and then before each treatment fraction Exclusion Criteria: - Previous radiotherapy in the pelvis - Tumor localized at less than 3 mm from the urethra - History of inflammatory colitis (including Crohn's disease and ulcerative colitis) - Prior cancer in the pelvis - Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before inclusion in the trial

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Stereotactic Body Radiation Therapy (SBRT)


Locations

Country Name City State
Switzerland Centre Hospitalier Universitaire Vaudois Lausanne

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire Vaudois

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose (phase I) Observation of dose-limiting toxicities (DLT) defined as any treatment-related grade = 3 acute toxicity occurring in the radiation field or irradiated volumes in the following categories GI or GU. In addition, any other grade 4 or 5 toxicity attributed to the therapy constitutes a DLT. During the first 30 days from the start of treatment
Primary Toxicity (phase II) Acute GU and GI toxicity (grade 2 or more) according to the NCI CTCAE v4.0. 90 days after the first fraction of radiotherapy treatment
Secondary Efficacy (phase II) PSA failure using Phoenix definition 3 monthly assessments during the first 2 years and 6 monthly assessments until end of study (5 years)
Secondary Toxicity (phase II) Long term GU and GI toxicity (grade 2 or more) according to the NCI CTCAE v4.0. > 90 days and up to 5 years from the start of protocol treatment
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03796767 - Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer Phase 2
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT05735223 - A Prospective Study to Evaluate the Impact of Maximal Urethral Length Preservation Technique During Robotic Laparoscopic Prostatectomy on the Stretched Flaccid Penile Length and Continence N/A
Recruiting NCT04175431 - Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study Phase 2
Completed NCT05197257 - 68Ga-PSMA-11 PET in Patients With Prostate Cancer Phase 3
Withdrawn NCT03982173 - Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors Phase 2
Terminated NCT02491411 - Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel N/A
Active, not recruiting NCT05496959 - 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study Phase 2
Completed NCT02940262 - Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy Phase 3
Recruiting NCT04391556 - Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic Adenocarcinoma Phase 2
Enrolling by invitation NCT03503643 - Hemi-Gland Cryoablation for Prostate Cancer at UCLA
Recruiting NCT05832086 - Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes Phase 2
Suspended NCT05064111 - Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy
Not yet recruiting NCT04031378 - Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer Phase 2
Recruiting NCT02600156 - Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors N/A
Recruiting NCT05726292 - A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer Phase 2
Recruiting NCT04423211 - Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging Phase 3
Terminated NCT03718338 - Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With Prostate Adenocarcinoma
Terminated NCT02564549 - MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Ca N/A
Recruiting NCT04983862 - Fluorescent Imaging of Nerves With Illuminare-1 During Surgery Phase 1